Gilead Sciences Strikes $7.8B Deal for Legend Biotech’s CAR-T Therapy to Challenge J&J
Gilead Sciences agreed to pay $7.8 billion for Legend Biotech's cilta‐cel CAR-T therapy, including $1.8 billion upfront and up to $6 billion in milestone payments. Legend Biotech will record immediate revenue and could earn substantial long-term cash flow as cilta-cel competes with Johnson & Johnson's multiple myeloma treatment.
1. Deal Structure
Gilead Sciences will pay Legend Biotech $1.8 billion upfront for global rights to cilta-cel and up to $6 billion in contingent payments tied to regulatory and sales milestones, securing exclusive commercialization in multiple territories.
2. Rationale and Timing
The acquisition is designed to challenge Johnson & Johnson’s Carvykti in relapsed or refractory multiple myeloma, with Gilead targeting approvals in the US, EU and Asia by late 2026 to capture growing market share.
3. Financial Impact for Legend Biotech
Legend Biotech will recognize the full upfront payment immediately, bolstering its balance sheet, while future milestones will provide upside linked to cilta-cel’s commercial success and accelerate its cash flow profile.
4. Competitive Outlook
The CAR-T market for multiple myeloma is projected to exceed $5 billion annually by 2027, and this deal deepens the rivalry between Gilead and Johnson & Johnson in the high-growth immunotherapy sector.